ClinicalTrials.gg
CompletedNCT04580641Q-MIGALUpdated Nov 17, 2026

Validation of a Questionnaire for Allodynia in Migraine.

An observational study in Migraine, sponsored by University Hospital, Clermont-Ferrand. Completed at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospital, Clermont-Ferrand · Observational

How we know

Updated Nov 17, 2026Now CompletedResults publication added+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
329
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Migraine Disorders with a site in France — 14 open to participants now, 20 under way, 6 of them phase 3. Migraine Disorders · France.

Enrollment
6th of 20
329 · median 155
Started
2020
with 6 others
Observational
20 of 71
4 open now
Registered
41st of 71
by date
Lead sponsor
9 of 71
University Hospital, Clermont-Ferrand

Among the 71 studies in Migraine Disorders with a site in France, this one is the 6th largest by enrollment of the 20 observational ones that give a count, is one of 7 that started in 2020, is one of 20 observational ones, and was the 41st registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

14 of the 71 studies in Migraine Disorders with a site in France are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Migraine Disorders with a site in France, or all of them as a file.
02

Study summary

Migraine is very frequent (15% of the general population). During attacks, many subjects with migraine have allodynia (pain induced by normally non-painful stimuli), photophobia (hypersensitivity to light), phonophobia (hypersensitivity to sound) or osmophobia (hypersensitivity to odours). The goal of the present study is to validate a new questionnaire made of 4 parts evaluating the presence of these 4 types of hypersensitivity, both during or between migraine attacks. It will allow to look for associations of these 4 symptoms and association of hypersensitivity with patients' or migraine's characteristics.

Read the detailed description

The prevalence of migraine is around 15% worldwide (GBD 2016, Lancet Neurol 2018). During attacks, and even between attacks, especially when migraine frequency is high, many subjects with migraine present with photophobia, phonophobia, osmophobia or allodynia. These symptoms are though to correspond to central sensitization and can be found in animal models of migraine (Boyer et al., Pain 2017; Dallel et al., Cephalalgia 2018).

These 4 symptoms have been studied separately in previous studies but to date, there is no overall questionnaire evaluating these 4 sub-types of hypersensitivity. The investigators have constituted a questionnaire based on previous validated questionnaires that have been translated into French (Lipton et al., 2008 for cutaneous allodynia; Choi et al., 2009 for photophobia), a previous questionnaire validated in French (Khalfa et al, 2002 for phonophobia) and created a few questions for each of the 4 symptoms, including osmophobia.

03

Conditions studied

  • Migraine

Keywords

  • migraine
  • allodynia
  • photophobia
  • phonophobia
  • osmophobia
  • central sensitization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects fulfilling 2018 international headache society criteria for migraine

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects fulfilling 2018 international headache society criteria for migraine.
  • Age > 17 years.
  • Written consent.

Exclusion criteria

Exclusion Criteria:

  • Presence of neurological comorbidities that could lead to sensorial or sensitive abnormalities
  • Presence of dermatological comorbidities that could lead to sensorial or sensitive abnormalities
  • Presence of ENT comorbidities that could lead to sensorial or sensitive abnormalities
  • Significant cognitive dysfunction precluding proper completion of the self-administered questionnaire
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
329 participants (actual)
Patient registry
No

Groups and cohorts

  • Subjects with migraine

    No medical intervention. All included subjects will filled in the questionnaire concerning migraine characteristics and associated symptoms.

    Other: Questionnaire

Interventions

  • OtherQuestionnaire

    A self-administered questionnaire will be completed by each study subject

06

What researchers measure

Primary outcomes

  1. Predictive factors of allodynia/hypersensitivity in subjects with migraine

    Correlations between scores on specific questionnaires evaluating allodynia/hypersensitivity (cutaneous allodynia with the questionnaire by Lipton et al., 2008, osmophobia with a home-made questionnaire rated from 0 to 4, photophobia with the questionnaire by Choi et al., 2009, phonophobia with the questionnaire by Khalfa et al., 2002), patients characteristics (age, sex, Body mass index, habits, score on the Hospital Anxiety and Depression scale) and migraine characteristics (presence of aura or not, migraine duration in years, migraine frequency in attacks per month, pain intensity during migraine attacks rated from 0 to 4).

    Time frame: baseline

Secondary outcomes

  1. Predictive factors of cutaneous allodynia in subjects with migraine

    Correlations between score on the 12-item Allodynia Symptom Checklist (Lipton et al., 2008) (score from 0 to 24 with higher values indicating higher level of allodynia), patients characteristics (age in years, sex, body mass index in kg/m², consumption of alcohol and tobacco, score on the Hospital Anxiety and Depression scale) and migraine characteristics (presence of aura or not, migraine duration in years, migraine frequency in attacks per month, pain intensity during migraine attacks rated from 0 to 4) .

    Time frame: baseline

  2. Predictive factors of photophobia in subjects with migraine

    Correlations between scores on two specific questionnaires evaluating photophobia (Choi et al., 2009; binary score for presence or absence of photophobia and home-made questionnaire with score from 0 to 4 with higher values indicating higher level of phonophobia), patients characteristics (age in years, sex, body mass index in kg/m², consumption of alcohol and tobacco, score on the Hospital Anxiety and Depression scale) and migraine characteristics (presence of aura or not, migraine duration in years, migraine frequency in attacks per month, pain intensity during migraine attacks rated from 0 to 4).

    Time frame: baseline

  3. Predictive factors of phonophobia in subjects with migraine

    Correlations between scores on a questionnaire evaluating phonophobia (Khalfa et al. 2002, score from 0 to 42 with higher values indicating higher level of phonophobia), patients characteristics (age in years, sex, body mass index in kg/m², consumption of alcohol and tobacco, score on the Hospital Anxiety and Depression scale) and migraine characteristics, (presence of aura or not, migraine duration in years, migraine frequency in attacks per month, pain intensity during migraine attacks rated from 0 to 4).

    Time frame: baseline

  4. Predictive factors of osmophobia in subjects with migraine

    Correlations between scores on a specific home-made questionnaire evaluating osmophobia (score from 0 to 4 with higher values indicating higher level of osmophobia), patients characteristics (age in years, sex, body mass index in kg/m², consumption of alcohol and tobacco, score on the Hospital Anxiety and Depression scale) and migraine characteristics (presence of aura or not, migraine duration in years, migraine frequency in attacks per month, pain intensity during migraine attacks rated from 0 to 4).

    Time frame: baseline

07

Study locations

14 sites
  • CH d'Annecy, Centre d'Etude et de Traitement de la Douleur
    Annecy, 74000, France
  • Cabinet de Neurologie
    Clermont-Ferrand, 63000, France
  • CHU de Clermont-Ferrand, Centre d'Etude et de Traitement de la Douleur
    Clermont-Ferrand, 63000, France
  • CHU de Clermont-Ferrand, Service de Neurologie
    Clermont-Ferrand, 63000, France
  • CH Emile Roux Le Puy en Velay, Service de Neurologie
    Le Puy-en-Velay, 43000, France
  • CHU de Lille, Service de Neurologie
    Lille, France
  • CHU de Lyon, Hôpital Pierre Wertheimer, Service de neurologie fonctionelle et épileptologie
    Lyon, 69000, France
  • Assistance Publique - Hôpitaux de Marseille, CHU La Timone, Centre d'Evaluation et Traitement de la Douleur
    Marseille, 13000, France
  • CHU de Montpellier, Service de Neurologie
    Montpellier, 34000, France
  • CHU de Nantes, Service de Neurologie
    Nantes, 44000, France
  • CHU de Nice, Département Evaluation et Traitement de la Douleur
    Nice, 06000, France
  • Assistance Publique - Hôpitaux de Paris, CHU Lariboisière, Service de Neurologie
    Paris, 75000, France
  • CHU de Rouen, Service de Neurologie
    Rouen, 76000, France
  • CH de Vichy, Service de Neurologie
    Vichy, 03200, France
08

References and documents

Publications

  • Choi JY, Oh K, Kim BJ, Chung CS, Koh SB, Park KW. Usefulness of a photophobia questionnaire in patients with migraine. Cephalalgia. 2009 Sep;29(9):953-9. doi: 10.1111/j.1468-2982.2008.01822.x. Epub 2009 Feb 27. PubMed 19298545 ↗
  • Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, Stewart WF; American Migraine Prevalence Prevention Advisory Group. Cutaneous allodynia in the migraine population. Ann Neurol. 2008 Feb;63(2):148-58. doi: 10.1002/ana.21211. PubMed 18059010 ↗
  • Khalfa S, Dubal S, Veuillet E, Perez-Diaz F, Jouvent R, Collet L. Psychometric normalization of a hyperacusis questionnaire. ORL J Otorhinolaryngol Relat Spec. 2002 Nov-Dec;64(6):436-42. doi: 10.1159/000067570. PubMed 12499770 ↗
  • Gabrielli F, Zuel M, Magaud C, Sickout-Arondo S, Pereira B, Dassa J, De Gaalon S, Demarquay G, Donnet A, Ducros A, Giraud P, Guegan-Massardier E, Lucas C, Mawet J, Najjar M, Roos C, Van Obberghen EK, Duale C, Dallel R, Moisset X. Validation of an 8-item self-administered questionnaire for assessing migraine-related sensory hypersensitivities (MHQ-8). J Headache Pain. 2025 May 26;26(1):128. doi: 10.1186/s10194-025-02067-3. PubMed 40414872 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2020 to primary completion in Feb 2021, 4 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2021 → Feb 2021, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2020
First posted
Oct 8, 2020
StartActual
Oct 22, 2020
Primary completionActual
Feb 28, 2021was Jun 2021
CompletionActual
Sep 30, 2021
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 17, 2026
Start date
Oct 1, 2020→Oct 22, 2020 (actual)
Nov 17, 2026
Primary completion
Jun 2021→Feb 28, 2021 (actual)
Nov 17, 2026
Enrollment
180 (estimated)→329 (actual)
Nov 17, 2026
Publications
Results publication added: Gabrielli F, Zuel M, Magaud C, Sickout-Arondo S, Pereira B, Dassa J, De Gaalon S, Demarquay G, Donnet A, Ducros A, Giraud P, Guegan-Massardier E, Lucas C, Mawe… PubMed 40414872 ↗
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Status unknown→Completed
    Publications Results publication added: Gabrielli F, Zuel M, Magaud C, Sickout-Arondo S, Pereira B, Dassa J, De Gaalon S, Demarquay G, Donnet A, Ducros A, Giraud P, Guegan-Massardier E, Lucas C, Mawe… PubMed 40414872 ↗
    Start date Oct 1, 2020→Oct 22, 2020 (now actual)
    Primary completion Jun 2021→Feb 28, 2021 (now actual)
    Enrollment 180 (estimated)→329 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04580641
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Oct 22, 2020
Primary completion
Feb 28, 2021
Completion
Sep 30, 2021
Last update
Nov 17, 2026

Study contacts

Xavier Moisset, MD, PhD
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion